Date published: 2026-3-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

BAZ2A Inhibitors

BAZ2A inhibitors comprise a distinct and intricate chemical class renowned for their intricate role in modulating the activity of the BAZ2A protein. These compounds exhibit a specific propensity for engaging with the catalytic site of the BAZ2A protein, thereby eliciting a remarkable influence on its inherent functionality. BAZ2A, acknowledged for its possession of bromodomain and PHD finger motifs, occupies a significant niche in the realm of chromatin remodeling and epigenetic orchestration. The inhibitors engineered for BAZ2A meticulously home in on its binding domains, orchestrating a meticulously choreographed disruption of its intrinsic capacity to discern acetylated lysine residues located on histone proteins.

This molecular recognition stands as a pivotal tether for the recruitment of intricate chromatin remodeling complexes to highly specific genomic locales. Through the strategic obfuscation of this recognition process, BAZ2A inhibitors ostensibly incite a cascading effect that resonates with the very architecture of chromatin, thereby exerting an indelible imprint on the elaborate tapestry of gene expression patterns. Intriguingly, the chemical moieties constituting BAZ2A inhibitors are meticulously architected to ensure a nexus of robust and selective interactions with the target protein, thereby perpetuating a finely tuned disruption of its conventional functioning. As the scientific journey unfolds, researchers ardently strive to unravel the labyrinthine intricacies governing the enigmatic interplay between BAZ2A inhibitors and the intricate topography of the protein's active sites, potentially unfurling novel vistas for comprehending the choreography of epigenetic regulation and the captivating dynamics of chromatin configuration.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BI 9564

1883429-22-8sc-507350
1 mg
$83.00
(0)

BI-9564 is another small molecule inhibitor that targets the BAZ2A bromodomain. It has been developed for its potential to disrupt BAZ2A-mediated epigenetic regulation and has been studied in various cancer models.

RVX 208

1044870-39-4sc-472700
10 mg
$340.00
(0)

RVX-208 is a selective BET bromodomain inhibitor that can also target BAZ2A due to its structural similarities to other bromodomain inhibitors.

A-485

1889279-16-6sc-507493
5 mg
$275.00
(0)

While primarily a BET inhibitor, A-485 has been found to also interact with BAZ2A and inhibit its activity. This broad-spectrum inhibitor could have potential in targeting multiple epigenetic pathways.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

JQ1 is a well-known BET inhibitor that has shown efficacy in inhibiting BAZ2A as well. It has been researched in various cancer contexts for its potential to disrupt epigenetic regulation.